Takeda’s narcolepsy drug approved by the FDA, a boon for new class of treatments

The U.S. Food and Drug Administration approved a new narcolepsy treatment developed by Takeda on Wednesday. The medication is administered as a twice-a-day pill designed to address the symptoms of the sleep disorder.

This approval marks the introduction of a novel drug class for narcolepsy. Scientists anticipate that this therapeutic approach may improve the treatment of sleep disorders and potentially offer applications for a broader range of neurological conditions.